Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo- C Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study of IA-14069

NCT05317741
View directory record Official record
Conditions
Healthy
Interventions
IA-14069, Placebo
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 26, 2026, 5:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

NCT03571594
View directory record Official record
Conditions
Acromegaly
Interventions
ONO-5788, ONO-5788 Placebo, Octreotide
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis

NCT03829683
View directory record Official record
Conditions
Alcoholic Hepatitis, Sepsis
Interventions
Vitamin C, Dextrose 5% in water
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 26, 2026, 5:17 AM EDT
Withdrawn Phase 2 Interventional

Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus

NCT03502694
View directory record Official record
Conditions
Metapneumovirus
Interventions
Lumicitabine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Fresno, California • Long Beach, California • Eustis, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 4 Interventional Results available

Niacin and Endothelial Function in Early CKD

NCT00852969
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Niacin, Active Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

CBD-Microglia PET Study

NCT04398719
View directory record Official record
Conditions
CBD, Healthy
Interventions
[11C]PBR28, Low-dose lipopolysaccharide, Intradermal Capsaicin
Radiation · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 1Phase 2 Interventional

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis

NCT02718495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PTI-428, Placebo
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 26, 2026, 5:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Upadacitinib (ABT-494), Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
147
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 1 Interventional

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers

NCT02833389
View directory record Official record
Conditions
Neuropathic Diabetic Foot Ulcers
Interventions
Placebo, UTTR1147A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Mesa, Arizona • San Francisco, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 26, 2026, 5:17 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

NCT04746924
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Tislelizumab, Ociperlimab, Pembrolizumab, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

NCT01074008
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, ABT-333, Ritonavir, Peginterferon alpha-2a, Ribavirin, Placebo
Drug · Other
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Response to Chardonnay Grape Marc Powder

NCT03203915
View directory record Official record
Conditions
Dyslipidemia, Obesity
Interventions
Chardonnay grape marc marc high polyphenol dose (120mg), Chardonnay grape marc powder low polyphenol dose (75mg), Placebo (0mg)
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
35 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

NCT01355289
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Los Angeles, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Not applicable Interventional

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

NCT04828668
View directory record Official record
Conditions
Covid 19
Interventions
Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Dietary Supplement
Lead sponsor
Endourage, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Emotional and Motivational Development to Support Well-being and Retention in Diverse University Students

NCT05294913
View directory record Official record
Conditions
Healthy
Interventions
Contextualized Wish-Outcome-Obstacle-Plan (WOOP) intervention, Placebo
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 4 Interventional Results available

Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo

NCT02062710
View directory record Official record
Conditions
Cough Reflex Sensitivity
Interventions
diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo, dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin Dose Determination Study

NCT01530178
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sitagliptin, Placebo Oral Tablet
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
13 Years to 30 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

NCT01007435
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
61
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 26, 2026, 5:17 AM EDT
Recruiting Phase 3 Interventional

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT07513376
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
24
States / cities
Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

NCT00882908
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of ONO-2020 in Healthy Participants

NCT05507515
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ONO-2020, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 1 Interventional

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

NCT01856426
View directory record Official record
Conditions
Hepatitis C
Interventions
EDP239, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Miami, Florida • San Antonio, Texas • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 26, 2026, 5:17 AM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 5:17 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

NCT04562155
View directory record Official record
Conditions
Refractory and/or Unexplained Chronic Cough
Interventions
BAY1817080, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Los Angeles, California • Largo, Florida • White Marsh, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 26, 2026, 5:17 AM EDT